about
Vascular Remodelling and Mesenchymal Transition in Systemic SclerosisRaynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementOxidized low-density lipoprotein alters the effect of matrix stiffness on the formation of endothelial networks and capillary lumens.Diagnosis and management of pulmonary hypertension in systemic sclerosis.Non-invasive assessment of skin microvascular function in humans: an insight into methods.Vasculitis in systemic sclerosis.Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular diseaseTelangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertensionSystemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunctionMechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis.Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro.Biomarkers in systemic sclerosis.Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.The pathogenesis, diagnosis and treatment of Raynaud phenomenon.T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.Digital ulcers secondary to Sneddon's syndrome successfully treated with Bosentan: not only useful in Systemic Sclerosis.Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study.Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.Vascular Evaluation of the Hand by Power Doppler Ultrasonography and New Predictive Markers of Ischemic Digital Ulcers in Systemic Sclerosis: Results of a Prospective Pilot Study.[Digital ulcers in systemic scleroderma].Clinical significance of anti-endothelial cell antibody in allogeneic hematopoietic stem cell transplantation recipients with graft-versus-host disease.A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults.Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon.Short course of simvastatin has no effect on markers of endothelial activation in normolipidemic patients with systemic sclerosis.Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin
P2860
Q26749091-4E4500F6-06A5-4B65-9F7D-4510F0980806Q28392431-EF7CB0CE-A10B-491A-97EB-D400D84A85D0Q33806149-26467FC4-08CC-46C6-914E-90EA3885F8BDQ33832379-B1078E9D-AB65-4540-BF51-77B44A3755CFQ34007539-8E1A2758-B9B1-4162-9241-DB6024B7AC96Q34189036-127E148D-921E-4709-92D5-53B405BD848FQ34192783-D2DE5D4B-393F-4CA9-8A95-120CE707C5ACQ34409802-0A13AB65-D073-41D1-9B61-1B5C67AAD475Q35495068-EAC0997A-DAB5-4F3D-AAA0-23AD76466B3BQ36051828-7C4DD1DE-20BF-44BC-83F5-9C03127D7C24Q36130814-C43F497B-EE1E-4BD3-91F0-AB20306AFE53Q36165049-91787532-5B50-43BF-A37E-2B169C542A50Q36590463-2A4B904A-82FB-49F8-AB86-F34675361C32Q37310583-4D9AD369-174B-456E-BDB2-33EFD88C39E3Q37629847-806FD02D-2782-4512-A3DF-CD8DABC83B9BQ37730018-612E7E49-8E0C-4128-B385-2AB78FB5E9A2Q37768336-0E5C1D92-27EB-4E8C-A5BC-06DD83A36D50Q38025285-EFAAEE90-7367-4DA7-9D9E-5ABC01EA9BEEQ38601631-D1A83495-467D-4076-A182-071136F51D83Q38749160-0ABB6A05-AD92-4348-BA1C-EEEF0333E692Q39365687-EB84C110-386E-4942-AB50-29CF223A6428Q39966988-BEA05141-405E-494A-81B6-5549D14DA062Q40087579-C26FD763-3C11-4235-B1A5-3B51BE141575Q40371203-E534B547-FC96-4E3E-BC86-7F9C431DA98CQ40387840-9524C271-D28B-48E9-B9BA-A6D362845B13Q41692409-D0C67660-AE7D-4437-A469-C101B011750AQ44322030-94129450-291B-4170-91FE-08D2D6D56274Q48115705-3AAB1A93-C30A-4B61-A124-7692E3934F2CQ52345956-4352DAFA-7AB0-4F33-ADA4-E9A40ACAB499Q55362089-0AD2C152-38E6-44A3-A049-0AE91261BDA7Q57486499-4F2BD191-4E6A-4B8E-BA8E-A56ECB73E907
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vascular disease in scleroderma.
@en
Vascular disease in scleroderma.
@nl
type
label
Vascular disease in scleroderma.
@en
Vascular disease in scleroderma.
@nl
prefLabel
Vascular disease in scleroderma.
@en
Vascular disease in scleroderma.
@nl
P2860
P1476
Vascular disease in scleroderma.
@en
P2093
Fredrick M Wigley
P2860
P2888
P304
P356
10.1007/S12016-008-8106-X
P577
2009-06-01T00:00:00Z